Both promise and peril exist for drugmakers in working with diagnostic tests to commercialize new medications or refine the applicability of existing ones
Team-Up seeks to bring manufacturers and logistics providers together
Today’s evolving healthcare environment calls for more collaboration in bringing drugs to market
The pharma industry needs to go farther in adapting to new marketplace realities
Securing your supply chain
Drug sponsors have options in both how the new FDA risk programs are structured and how to execute them
Optimized multichannel communications will prevent illness and save lives
Today’s uncertain work environment obliges you to manage your career and financial status to keep your options open
Marketing strategies will adjust with the advent of biosimilars
Overestimating product reserves as loss of exclusivity (LoE) approaches can be a $75-million mistake
As more of these novel—and costly—cell therapies gain approval, revamped strategies around scaling, coordination and workflow are critical to their launch
Logistics managers in life sciences and personal care focus on transportation capacity
Recent regulatory actions and court cases highlight the importance of due diligence in reporting the value of service fees when federal reimbursements are concerned. The financial consequences can be substantial
Multi-tenant sales-force automation (SFA) systems are coping with an increasingly complex regulatory environment
As the number of adverse events (AEs) grows year by year, regulators and industry managers are looking at automated systems to handle the burden
Begin thinking of your business as a 'disease' company vs. a 'drug' company
The rise of the patient voice and increased acceptance of remote engagement are sparking a culture change across the supply chain
Risk Evaluation & Mitigation Strategy (REMS) programs are evolving, with new complexities for compliance managers
Could proposed legislation undercut the promise of targeted therapies?
For global markets, there is a need to balance the imperative to get to market quickly against the evolving regulatory landscape
Addressing continued hurdles in patient adherence
Visual aids, diminished for a time as a marketing and educational tool because of industry restrictions, are making a comeback
It takes gritty work to make an AI application succeed—but it can be worth the effort
Private and public sectors can collaborate to achieve meaningful reform
Better internal collaboration within companies is critical to improving the vital physician-rep relationship
Rare diseases are hard to treat; supporting the patient can be even more challenging